# EMA Panel Recommends Expanded Use of Merck’s Enflonsia in Europe

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/56911
Published: 2026-11-13T17:21:12.000Z
Updated: 2026-11-13T17:21:12.000Z
Section: Regulation

> The Committee for Medicinal Products for Human Use backed a broader indication for the RSV prevention treatment, whose active ingredient is clesrovimab.

The Committee for Medicinal Products for Human Use, part of the European Medicines Agency (EMA), recommended approval of an expanded indication for Merck’s Enflonsia (clesrovimab), an RSV prevention treatment.

The endorsement moves the proposed change through the European review process toward approval.